Sinovac Biotech Ltd (SVA) - Total Assets
Based on the latest financial reports, Sinovac Biotech Ltd (SVA) holds total assets worth $12.90 Billion USD as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SVA net asset value for net asset value and shareholders' equity analysis.
Sinovac Biotech Ltd - Total Assets Trend (1998–2023)
This chart illustrates how Sinovac Biotech Ltd's total assets have evolved over time, based on quarterly financial data.
Sinovac Biotech Ltd - Asset Composition Analysis
Current Asset Composition (December 2023)
Sinovac Biotech Ltd's total assets of $12.90 Billion consist of 86.6% current assets and 13.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.3% |
| Accounts Receivable | $450.72 Million | 3.3% |
| Inventory | $139.87 Million | 1.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $8.52 Million | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2023)
This chart illustrates how Sinovac Biotech Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sinovac Biotech Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinovac Biotech Ltd's current assets represent 86.6% of total assets in 2023, a decrease from 100.0% in 1998.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2023, down from 100.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 3.3% of total assets.
Sinovac Biotech Ltd Competitors by Total Assets
Key competitors of Sinovac Biotech Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merus BV
NASDAQ:MRUS
|
USA | $771.99 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Savara Inc
NASDAQ:SVRA
|
USA | $140.92 Million |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥2.96 Billion |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Sinovac Biotech Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.39 | 9.89 | 4.35 |
| Quick Ratio | 11.24 | 9.74 | 3.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.17 Billion | $10.58 Billion | $233.97 Million |
Sinovac Biotech Ltd - Advanced Valuation Insights
This section examines the relationship between Sinovac Biotech Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.82 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -3.2% |
| Total Assets | $13.66 Billion |
| Market Capitalization | $642.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sinovac Biotech Ltd's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Sinovac Biotech Ltd's assets decreased by 3.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sinovac Biotech Ltd (1998–2023)
The table below shows the annual total assets of Sinovac Biotech Ltd from 1998 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $13.66 Billion | -3.23% |
| 2022-12-31 | $14.11 Billion | -15.72% |
| 2021-12-31 | $16.75 Billion | +780.87% |
| 2020-12-31 | $1.90 Billion | +320.37% |
| 2019-12-31 | $452.30 Million | +22.32% |
| 2018-12-31 | $369.78 Million | +74.96% |
| 2017-12-31 | $211.35 Million | 0.00% |
| 2016-12-31 | $211.35 Million | +4.15% |
| 2015-12-31 | $202.93 Million | -14.93% |
| 2014-12-31 | $238.53 Million | -0.90% |
| 2013-12-31 | $240.69 Million | +15.29% |
| 2012-12-31 | $208.76 Million | -3.31% |
| 2011-12-31 | $215.91 Million | +0.72% |
| 2010-12-31 | $214.36 Million | +47.35% |
| 2009-12-31 | $145.48 Million | +87.86% |
| 2008-12-31 | $77.44 Million | +34.80% |
| 2007-12-31 | $57.45 Million | +55.23% |
| 2006-12-31 | $37.01 Million | +58.38% |
| 2005-12-31 | $23.37 Million | +4.22% |
| 2004-12-31 | $22.42 Million | +50.49% |
| 2003-12-31 | $14.90 Million | +6205.80% |
| 2002-12-31 | $236.25K | -12.24% |
| 2001-12-31 | $269.19K | 0.00% |
| 2000-12-31 | $269.19K | +703.40% |
| 1999-12-31 | $33.51K | 0.00% |
| 1998-12-31 | $33.51K | -- |
About Sinovac Biotech Ltd
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more